Endocrinology Education and CME

My Education
Keep track of all your educational activities here
  • Access activities already in progress
  • See credits earned to date
  • Print certificates
  • Top Picks
    • Challenges in Prescribing PCSK9 Inhibitors: An Expert Interview
    • Improving Bone Strength and Reducing Fracture Risk in Osteoporosis
    • Practical Lipidology®: Volume 3, Number 2
    • In My Setting: Diabetes Care

Select a Topic

  • FILTER BY:
J294
CME

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis

This activity is supported by an educational grant from Merck & Co., Inc.

Expiration Date: 9/15/2017
Credit Type(s): CME / ABIM/CME | Credit: 1.5

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to reduced bone strength and a consequent increase in fracture…

go to activity»
Diabetic Retinopathy: Preferred Practice Patterns in Screening and Management
CMECNECE

Diabetic Retinopathy: Preferred Practice Patterns in Screening and Management

This activity is supported by an educational grant from Regeneron.

Expiration Date: 8/10/2017
Credit Type(s): CME / CNE / AANP / AAPA | Credit: 1.5

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence of DR in this population is increasing; it…

go to activity»
In My Setting: Diabetes Care

Read what three clinicians have to say about the current state of diabetes treatment options….

go to activity»
Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk
CMECE

Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk

This activity is supported by an educational grant from Genzyme, a Sanofi company, sanofi-aventis U.S., and Regeneron Pharmaceuticals.

May 20, 2016

This digital monograph, featuring video snippets and key slides from the 2015 CMHC Annual meeting examines current lipid guidelines, the unmet need and residual risk of…

go to activity»
New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice
CME

New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 3/10/2017
Credit Type(s): CME | Credit: 1

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»
j319
CME

Practical Lipidology®: Volume 3, Number 2

This activity is supported by an educational grant from Amgen

Expiration Date: 9/1/2017
Credit Type(s): CME | Credit: 1.25

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing cardiovascular risk. Despite highly effective statin…

go to activity»
j319
CME

Practical Lipidology®: Volume 3, Number 1

This activity is supported by an educational grant from Amgen

Expiration Date: 7/1/2017
Credit Type(s): CME | Credit: 1.25

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing cardiovascular risk. Despite highly effective statin…

go to activity»
Challenges in Prescribing PCSK9 Inhibitors

Challenges in Prescribing PCSK9 Inhibitors: An Expert Interview

Support for this program is provided by Amgen and Sanofi-Regeneron

January 12, 2017

Watch these short videos and learn about the NLA‘s provider survey as well as some of the preliminary results found about the challenges to access PCSK9 therapy….

go to activity»
In My Setting Lipids

Catch up with three physicians as they provide insightful information on the topic of lipids….

go to activity»
J294
CME

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis

This activity is supported by an educational grant from Merck & Co., Inc.

Expiration Date: 9/15/2017
Credit Type(s): CME / ABIM/CME | Credit: 1.5

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to reduced bone strength and a consequent increase in fracture…

go to activity»
j319
CME

Practical Lipidology®: Volume 3, Number 2

This activity is supported by an educational grant from Amgen

Expiration Date: 9/1/2017
Credit Type(s): CME | Credit: 1.25

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing cardiovascular risk. Despite highly effective statin…

go to activity»
Diabetic Retinopathy: Preferred Practice Patterns in Screening and Management
CMECNECE

Diabetic Retinopathy: Preferred Practice Patterns in Screening and Management

This activity is supported by an educational grant from Regeneron.

Expiration Date: 8/10/2017
Credit Type(s): CME / CNE / AANP / AAPA | Credit: 1.5

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence of DR in this population is increasing; it…

go to activity»
j319
CME

Practical Lipidology®: Volume 3, Number 1

This activity is supported by an educational grant from Amgen

Expiration Date: 7/1/2017
Credit Type(s): CME | Credit: 1.25

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing cardiovascular risk. Despite highly effective statin…

go to activity»
In My Setting: Diabetes Care

Read what three clinicians have to say about the current state of diabetes treatment options….

go to activity»
Challenges in Prescribing PCSK9 Inhibitors

Challenges in Prescribing PCSK9 Inhibitors: An Expert Interview

Support for this program is provided by Amgen and Sanofi-Regeneron

January 12, 2017

Watch these short videos and learn about the NLA‘s provider survey as well as some of the preliminary results found about the challenges to access PCSK9 therapy….

go to activity»
Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk
CMECE

Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk

This activity is supported by an educational grant from Genzyme, a Sanofi company, sanofi-aventis U.S., and Regeneron Pharmaceuticals.

May 20, 2016

This digital monograph, featuring video snippets and key slides from the 2015 CMHC Annual meeting examines current lipid guidelines, the unmet need and residual risk of…

go to activity»
In My Setting Lipids

Catch up with three physicians as they provide insightful information on the topic of lipids….

go to activity»
New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice
CME

New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 3/10/2017
Credit Type(s): CME | Credit: 1

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»